MilliporeSigma Announces Completion of Schnelldorf Distribution Center Expansion

MilliporeSigma announced that its Life Science business opened a newly expanded distribution center in Schnelldorf, Germany

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced that its Life Science business has opened a newly expanded distribution center in Schnelldorf, Germany. The investment of € 180 million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and additional space for the distribution of a wide range of products to laboratories and research facilities all around the world. The site employs 470 engineers, manufacturing, and distribution experts.

By combining manual downing filling capabilities with our distribution expertise, our customers will benefit from increased product availability and quicker delivery,” said Matthias Heinzel, Member of the Executive Board and CEO Life Science, Merck KGaA, Darmstadt, Germany. “This is critical to ensuring that medicines reach patients faster, safely, and more efficiently. This is how we do our part to impact life and health with science.”

“With this expansion, Schnelldorf is becoming one of our flagship sites, providing unique end-to-end capabilities for our Life Science customers,” said Ivan Donzelot, Head of Integrated Supply Chain Operations, Life Science business of Merck KGaA, Darmstadt, Germany. “With the full integration of manufacturing and distribution in one site, our customers can now receive even faster and better service whether they are in Europe or in other regions of the world.”

The expansion of the Schnelldorf facility is part of a multi-year investment program of the company’s Life Science business. It aims to increase the capacity and capabilities to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, the Life Science business of Merck KGaA, Darmstadt, Germany has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.

The Life Science business of Merck KGaA, Darmstadt, Germany is comprised of more than 50 production and testing sites and 64 distribution centers around the world and has more than 27,000 employees in 65 countries.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version